TARO News and Press, Taro Pharmaceutical Industries Ltd. From 12/19/19

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today announced the final results of its modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares, nominal (par) value NIS 0.0001 p...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced the preliminary results of its modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares, nominal (par) value NIS 0...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has accepted the resignation of its Chief Financial Officer, Mariano Balaguer, effective January 3, 2020. Mr. Balaguer is leaving to accept the position of CFO at ano...

The FDA has granted tentative approval to Taro Pharmaceutical Industries' (NYSE: TARO ) tavaborole, the generic active ingredient in Kerydin (by Novartis (NYSE: NVS ) and Pfizer (NYSE: PFE )). More news on: Taro Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Healthcare stocks ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has commenced a modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares at a price not greater than $92.0...

Image source: The Motley Fool. Taro Pharmaceutical Industries   (NYSE: TARO) Q2 2019 Earnings Call Nov 05, 2019 , 8:00 a.m. ET Operator Continue reading

Taro Pharmaceutical Industries Ltd. (TARO) Q2 2020 Earnings Conference Call November 05, 2019 8:00 AM ET Company Participants William Coote - Assistant Vice President of Business Finance & Investor relations & Treasurer Dilip Shanghvi - Chairman of the Board of Directors ...

Taro Pharmaceutical (NYSE: TARO ): Q3 GAAP EPS of $1.46 misses by $0.26 . More news on: Taro Pharmaceutical Industries Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

Board of Directors Approves $300 Million Share Repurchase Program Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2019. Quarter ended ...

Earnings Call to Discuss Results to be Conducted Tuesday, November 5 at 8:00 am ET Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for quarter and six months ended September 30, 2019, on Monday, November 4, 2019. The C...